Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Fey

Showing results (121-130 of 161) with videos related to

Pageof 17
Sort By:
Schweizerische Medizinische Wochenschrift|May 16, 1987
[Hodgkin's disease in a Swiss family]M F Fey, R A Joss, W J Pichler, et al.
Archives of Gynecology and Obstetrics|November 28, 2017
Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservationA N Schüring, T Fehm, K Behringer, et al.
International Journal of Cancer|September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)T Cerny, M F Fey, R Oppliger, et al.
Oncogene|February 2, 1999
Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemiaU R Peters, U Hasse, E Oppliger, et al.
The Prostate|June 1, 1997
Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutationsA E Mottaz, R Markwalder, M F Fey, et al.
Oncogene|May 23, 2006
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophilsS Martinelli, G Kostylina, V Niggli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?J Bernhard, B Thürlimann, S F Schmitz, et al.
Blood|February 15, 1994
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probeM F Fey, S Liechti-Gallati, A von Rohr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemiasD C Betticher, M F Fey, A von Rohr, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Pageof 17

Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
Schweizerische Medizinische Wochenschrift|May 16, 1987
[Hodgkin's disease in a Swiss family]M F Fey, R A Joss, W J Pichler, et al.
Archives of Gynecology and Obstetrics|November 28, 2017
Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservationA N Schüring, T Fehm, K Behringer, et al.
International Journal of Cancer|September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)T Cerny, M F Fey, R Oppliger, et al.
Oncogene|February 2, 1999
Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemiaU R Peters, U Hasse, E Oppliger, et al.
The Prostate|June 1, 1997
Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutationsA E Mottaz, R Markwalder, M F Fey, et al.
Oncogene|May 23, 2006
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophilsS Martinelli, G Kostylina, V Niggli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?J Bernhard, B Thürlimann, S F Schmitz, et al.
Blood|February 15, 1994
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probeM F Fey, S Liechti-Gallati, A von Rohr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemiasD C Betticher, M F Fey, A von Rohr, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Pageof 17